Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial
Authors
Jianjiao Ni (ORCID: https://orcid.org/0000-0003-3113-2586)
Xi Yang (ORCID: https://orcid.org/0000-0001-6125-7641)
Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial
Jianjiao Ni, Xi Yang, Shanshan Jiang, Peng Lin et al.
Citations
22 citations
Journal
EClinicalMedicine
Topics
Lung Cancer Treatments and Mutations
Field-Weighted Citation Impact (FWCI)
9.22
article
Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial
Jianjiao Ni, Xi Yang, Shanshan Jiang, Peng Lin, Fei Liang, Tiantian Guo, Li Zhang, Junhua Zhang, Li Chu, Xiao Chu, Yue Zhou, Yechun Pang, Zhengfei Zhu, Zezhou Wang
article en
22 citations
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 76
Institutions
Shanghai Medical College of Fudan University (CN), Sun Yat-sen University (CN), Fudan University (CN), Fudan University Shanghai Cancer Center (CN), Zhongshan Hospital (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Tongji Hospital (CN), Huazhong University of Science and Technology (CN)